Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00110487
Status:
COMPLETED
Last Update Posted:
2015-05-01
First Post:
2005-05-09
Brief Title:
Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
A Double-Blind Randomized Placebo-Controlled Dose-Ranging Study of the Effect of ERB-041 in the Reduction of Symptoms Associated With Endometriosis in Reproductive-Age Women
Status:
COMPLETED
Status Verified Date:
2007-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this investigational study is to determine if a study medication is safe and effective in reducing the symptoms associated with endometriosis if the study medication reduces the need for pain medication for endometriosis symptoms and if the study medication improves a participants ability to carry out daily activities Qualified participants will receive no cost treatment which may include study-related examinations diagnostic procedures including a Pap smear laboratory testing and a mammogram aged 40-45 Qualified participants will also receive study medication at no cost As a participant the study volunteer may also experience the satisfaction of knowing she is helping the advancement of womens health care
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None